journal article·2025-05Open access

Orally Administered Functional Polyphenol‐Nanozyme‐Armored Probiotics for Enhanced Amelioration of Intestinal Inflammation and Microbiota Dysbiosis

Yong Zhu, Ziqu Fang, Jie Bai, Longhui Wang, Jiaqing Chen, Zehua Zhang, Qiang Wang, Weiwei Sheng, Xueyin Pan, Zhenyuan Gao, Dengqiu Xu, Pengkai Wu, Beicheng Sun

Advanced Science· Volume 12· Issue 17

Abstract

Abstract Maintaining microbiota balance and enhancing the antioxidant performance of nanozyme‐based probiotic systems are crucial for effective inflammatory bowel disease (IBD) therapy. Despite significant advancements, developing a green and safe coating technology that functionalizes probiotics with nanozymes while preserving the activity of both components remains a challenge. To address this, chitosan‐modified epigallocatechin gallate (EGCG‐CS, EC)is synthesized, leveraging the intrinsic adhesive and coordination properties of polyphenols to capture gold nanozymes (AuNPs), forming ECA complexes that enhance nanozyme activity. When coated onto Escherichia coli Nissle 1917 (EcN), the resulting ECA@EcN system effectively scavenged reactive oxygen species (ROS), improving probiotic viability and promoting colon accumulation. Mechanistically, ECA protected EcN by suppressing the activation of the Flagellar Assembly and Branched‐Chain Amino Acid Synthesis pathways, ultimately alleviating inflammation and modulating intestinal microbial communities to relieve IBD symptoms. Given the biocompatibility of its components and the environmentally friendly assembly approach, this polyphenol‐nanozyme‐armored probiotic system represents a promising platform for IBD treatment.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Advanced Nanomaterials in Catalysis · Nanocluster Synthesis and Applications · Nanoplatforms for cancer theranostics

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Hepatobiliary Surgery The First Affiliated Hospital of Anhui Medical University Hefei Anhui 230022 China

MOE Innovation Center for Basic Research in Tumor Immunotherapy Hefei Anhui 230022 China

Anhui Province Key Laboratory of Tumor Immune Microenvironment and Immunotherapy Hefei Anhui 230022 China

Department of General Surgery The First Affiliated Hospital of Anhui Medical University Hefei 230022 China

Funding

Natural Science Foundation of Jiangsu Province · National Natural Science Foundation of China

References (49)

Show source-provided references
1. 10.1016/S0140-6736(17)32448-010.1016/S0140-6736(17)32448-0 ↗
2. 10.1136/gutjnl-2021-32630510.1136/gutjnl-2021-326305 ↗
3. 10.1126/sciadv.abp988210.1126/sciadv.abp9882 ↗
4. 10.1038/nrgastro.2016.20810.1038/nrgastro.2016.208 ↗
5. 10.1002/adma.20210258010.1002/adma.202102580 ↗
6. 10.1038/s41565-023-01346-x10.1038/s41565-023-01346-x ↗
7. 10.1126/sciadv.abp879810.1126/sciadv.abp8798 ↗
8. 10.1002/smll.20230233110.1002/smll.202302331 ↗
9. 10.1021/acsnano.3c1037610.1021/acsnano.3c10376 ↗
10. 10.1021/acsnano.2c0618610.1021/acsnano.2c06186 ↗
11. 10.1126/science.123726510.1126/science.1237265 ↗
12. 10.1002/adma.20160327010.1002/adma.201603270 ↗
13. 10.1016/j.carbpol.2016.10.03810.1016/j.carbpol.2016.10.038 ↗
14. 10.1038/s41467-022-31171-010.1038/s41467-022-31171-0 ↗
15. 10.1080/10408398.2024.232818410.1080/10408398.2024.2328184 ↗
16. 10.1002/advs.20210589410.1002/advs.202105894 ↗
17. 10.1016/j.ijpharm.2022.12241910.1016/j.ijpharm.2022.122419 ↗
18. 10.1016/j.bioactmat.2024.01.01610.1016/j.bioactmat.2024.01.016 ↗
19. 10.1021/acsnano.3c0291410.1021/acsnano.3c02914 ↗
20. 10.1016/j.ijbiomac.2020.08.15310.1016/j.ijbiomac.2020.08.153 ↗
21. 10.1016/j.foodres.2022.11107310.1016/j.foodres.2022.111073 ↗
22. 10.1038/3504168710.1038/35041687 ↗
23. 10.1007/s10965-019-1893-310.1007/s10965-019-1893-3 ↗
24. 10.1002/smll.20230233110.1002/smll.202302331 ↗
25. 10.1038/s41467-022-33098-y10.1038/s41467-022-33098-y ↗
26. 10.1002/smll.20150391910.1002/smll.201503919 ↗
27. 10.1038/s41575-023-00769-010.1038/s41575-023-00769-0 ↗
28. 10.1038/s41575-019-0172-410.1038/s41575-019-0172-4 ↗
29. 10.1002/smll.20220691910.1002/smll.202206919 ↗
30. 10.1016/j.cmet.2015.06.00610.1016/j.cmet.2015.06.006 ↗
31. 10.1080/19490976.2022.210865510.1080/19490976.2022.2108655 ↗
32. Zhang J. · ACS Nano · 2019 · 13 · 2004
33. He T. · Acta Mater. Med. · 2023 · 2 · 466
34. 10.1016/j.ejps.2020.10528010.1016/j.ejps.2020.105280 ↗
35. 10.1038/s41929-024-01259-510.1038/s41929-024-01259-5 ↗
36. 10.1002/adma.20230872810.1002/adma.202308728 ↗
37. 10.1038/s41467-019-13336-610.1038/s41467-019-13336-6 ↗
38. 10.1002/advs.20230316710.1002/advs.202303167 ↗
39. 10.1002/advs.20210334310.1002/advs.202103343 ↗
40. 10.1002/adma.20220789010.1002/adma.202207890 ↗
41. 10.1038/s41575-020-0331-710.1038/s41575-020-0331-7 ↗
42. 10.1038/s41575-019-0258-z10.1038/s41575-019-0258-z ↗
43. 10.1136/gutjnl-2022-32838910.1136/gutjnl-2022-328389 ↗
44. 10.1038/s41467-024-45636-x10.1038/s41467-024-45636-x ↗
45. 10.1126/sciadv.adn174510.1126/sciadv.adn1745 ↗
46. 10.1016/j.foodchem.2018.09.04010.1016/j.foodchem.2018.09.040 ↗
47. 10.1016/j.actbio.2019.06.02310.1016/j.actbio.2019.06.023 ↗
48. 10.1002/adma.20230158510.1002/adma.202301585 ↗
49. 10.1021/acsami.0c0030310.1021/acsami.0c00303 ↗